Challenges of tuberculosis control

Murray, Sally
January 2006
CMAJ: Canadian Medical Association Journal;1/3/2006, Vol. 174 Issue 1, p33
Academic Journal
This article discusses challenges facing global tuberculosis control. A main problem in tuberculosis (TB) control can be attributed to diagnostic tools that are obsolete and inadequate, while drugs such as isoniazid and rifampicin carries the need for prolonged treatment. To facilitate compliance with these treatment, the World Health Organization introduced the directly observed therapy short course program which includes TB detection, regular supply of drugs and supervised treatment.


Related Articles

  • India Losing Battle Against Multi Drug Resistant Tuberculosis. Saxena, Anjali; Mukherjee, Udita; Dua, Ankita; Lal, Rup // Indian Journal of Microbiology;Dec2012, Vol. 52 Issue 4, p713 

    The article presents information on the Multi Drug Resistant (MDR) forms of tuberculosis (TB) that have developed due to partial or incomplete treatment. It informs that MDR-TB is an infectious air borne disease which is resistant to the most important primary drugs including rifampicin and...

  • Alternative Methods of Diagnosing Drug Resistanced-What Can They Do for Me? Moore, David A. J.; Shah, N. Sarita // Journal of Infectious Diseases;2011 Supplement 4, Vol. 204, pS1110 

    During the last decade considerable attention has been focussed upon the development of new technologies and methodologies for detection of drug resistance in Mycobacterium tuberculosis. There is a growing acknowledgement that the redundancy in testing a full panel of first-line drugs is an...

  • Latest TB figures are a "wake-up call for all governments" Moszymski, Peter // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;3/27/2010, Vol. 340 Issue 7748, p674 

    The article relates the warning issued by the World Health Organization (WHO) in March 2010 about the serious threat posed by the increasing incidence of drug resistant tuberculosis to world health. As disclosed, approximately 9.4 million new cases of tuberculosis and 1.8 million deaths were...

  • Drug Resistant Tuberculosis: A Worldwide Epidemic Poses a New Challenge. Loddenkemper, Robert; Hauer, Barbara // Deutsches Aerzteblatt International;1/7/2010, Vol. 107 Issue 1/2, p1 

    The article reports on the unexpected increase of cases of drug resistant tuberculosis (TB) around the world. The World Health Organization (WHO) found that an estimated 5% of more than nine million people with TB are known to have been infected with a multi-resistant strain to isoniazid and...

  • The Impact of Isoniazid Resistance on the Treatment Outcomes of Smear Positive Re-Treatment Tuberculosis Patients in the State of Andhra Pradesh, India. Deepa, Dorai; Achanta, Shanta; Jaju, Jyoti; Rao, Koteswara; Samyukta, Rani; Claassens, Mareli; Kumar, Ajay M. V.; PH, Vishnu // PLoS ONE;Oct2013, Vol. 8 Issue 10, p1 

    Background:Multi drug resistant and rifampicin resistant TB patients in India are treated with the World Health Organization (WHO) recommended standardized treatment regimens but no guidelines are available for the management of isoniazid (INH) resistant TB patients. There have been concerns...

  • NEW STRATEGIES FOR THE TREATMENT OF TUBERCULOSIS. Birluţiu, Victoria; Mitrea, Mirela // Therapeutics, Pharmacology & Clinical Toxicology;2009, Vol. 13 Issue 4, p370 

    The treatment of Tuberculosis may be associated with an emergence of mycobacterial resistance through chromosomal alterations, but also through a poor administration of treatment, leading to the emergence of multi-drug-resistant strains MDR-TB or extensively drug-resistant, XDR-TB, responsible...

  • NEW RAPID TESTS FOR DRUG-RESISTANT TB FOR DEVELOPING COUNTRIES.  // Indian Journal of Medical Sciences;Jun2008, Vol. 62 Issue 6, p252 

    The article reports on the development of rapid diagnostic tests for multi-drug resistant tuberculosis (MDR-TB) by the World Health Organization (WHO), Stop TB Partnership, UNITAID and the Foundation for Innovative New Diagnostics. MDR-TB is resistant to first-line drugs isoniazid and...

  • Evaluation of the modified colorimetric resazurin microtiter plate-based antibacterial assay for rapid and reliable tuberculosis drug susceptibility testing. Katawera, Victoria; Siedner, Mark; Boum II, Yap // BMC Microbiology;2014, Vol. 14 Issue 1, p2 

    Background The resazurin microtiter assay (classic REMA), a colorimetric liquid culture-based drug susceptibility assay for Mycobacterium tuberculosis (MTB), has been endorsed by the World Health Organization. The assay requires 8-16 days to obtain results, delaying management of drug resistant...

  • Antituberculosis drug-induced hepatotoxicity in children. Donald, Peter R. // Pediatric Reports;2011, Vol. 3 Issue 2, p51 

    Recent increases in the dosages of the essential antituberculosis agents isoniazid (INH), rifampicin (RMP), pyrazinamide (PZA) for use in children recommended by World Health Organization have raised concerns regarding the risk of hepatotoxicity. Published data relating to the incidence and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics